Zymeworks Gross Profit 2016-2022 | ZYME

Zymeworks gross profit from 2016 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Zymeworks Annual Gross Profit
(Millions of US $)
2021 $-173
2020 $-132
2019 $-86
2018 $-4
2017 $10
2016 $-26
2015 $-15
Zymeworks Quarterly Gross Profit
(Millions of US $)
2022-06-30 $-51
2022-03-31 $-61
2021-12-31 $-35
2021-09-30 $-45
2021-06-30 $-49
2021-03-31 $-44
2020-12-31 $-24
2020-09-30 $-52
2020-06-30 $-27
2020-03-31 $-29
2019-12-31 $-44
2019-09-30 $-21
2019-06-30 $-16
2019-03-31 $-6
2018-12-31 $15
2018-09-30 $-12
2018-06-30 $7
2018-03-31 $-13
2017-12-31 $37
2017-09-30 $-11
2017-06-30 $-7
2017-03-31 $-9
2016-12-31 $-7
2016-09-30 $-8
2016-06-30 $-4
2016-03-31 $-8
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.493B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.264B 10.27
GSK (GSK) United Kingdom $68.657B 8.61
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.145B 19.02
Ginkgo Bioworks Holdings (DNA) United States $3.570B 0.00
Myovant Sciences (MYOV) United Kingdom $2.594B 0.00
Arcus Biosciences (RCUS) United States $2.073B 31.12
Biohaven (BHVN) United States $0.982B 0.00
Emergent Biosolutions (EBS) United States $0.579B 4.55
ADC Therapeutics SA (ADCT) Switzerland $0.261B 0.00
Enzo Biochem (ENZ) United States $0.094B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00